Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
NCT02338232
·
clinicaltrials.gov ↗
NA
Phase
TERMINATED
Status
32
Enrollment
OTHER
Sponsor class
Stopped
Lack of Accrual
Conditions
GVHD
Interventions
DRUG:
Telmisartan
Sponsor
Hackensack Meridian Health